Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.
Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.
Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.
Illumina has secured an $8 million damages verdict against China-based BGI Genomics, and its US subsidiary, MGI, in a dispute involving gene-sequencing patents.
Moderna has failed to reverse an unfavourable ruling related to its COVID-19 vaccine technology, after the US Court of Appeals for the Federal Circuit upheld the validity of a patent owned by Arbutus Biopharma.
The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
The World Trade Organization has postponed its ministerial conference indefinitely, potentially ending the opportunity for countries to agree an IP waiver for COVID-19 vaccines this year.